Drugs / AD16
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05806177 | May → Jul 2020 | Alzheimer disease | South China Center For Innovative Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05787028 | Jan 2019 → May 2020 | Alzheimer disease | South China Center For Innovative Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD16 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05806177 ↗ |
| Route | Oral | “a single oral dose of AD16” NCT05787028 ↗ |